Immunotherapy startup Anaveon supported by UZH Life Sciences Fund
With the help of investments of the UZH Life Sciences Fund and the BaseLaunch funding programme, Onur Boyman and Andreas Katopodis founded the spin-off Anaveon AG. Onur Boyman, Director of the Department of Immunology at the University Hospital of Zurich and Professor at the Faculty of Medicine of the University of Zurich, and Andreas Katopodis, previously Director at the Novartis Institutes of Biomedical Research, have developed an antibody based on years of research by Onur Boyman. Anaveon plans to develop this antibody into a cancer drug. Melanoma and renal and lung carcinomas are the main indications.
Anaveon's antibody re-directs Interleukin-2, an immune growth factor, to preferential promote proliferation of a class of T-cells against cancer cells.
At the same time, the Anaveon-antibody reduces undesirable side effects of Interleukin-2 cancer therapy resulting in a better therapeutic window.
VISCHER advises Anaveon AG on legal and tax issues. The VISCHER team is led by Christian Wyss (Corporate) and Nadia Tarolli (Tax) and includes Moritz Jäggy (Corporate), Nora Heuberger (Tax), Fiona Gao (Corporate) and Sara Ianni (Employment).